Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPN | P05981 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | RAC1 | P63000 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7744761 | 0.91 | HPN (0.46) | HPNKDRFLT1FLT4SMN1; SMN2 | |
| SCHEMBL7744773 | 0.89 | HPN (0.41) | HPNSMN1; SMN2MAPTTP53 | |
| SCHEMBL7744196 | 0.88 | KDR (0.54) | KDRFLT1FLT4SMN1; SMN2MAPT | |
| SCHEMBL7986670 | 0.87 | KDR (0.50) | KDRFLT1FLT4SMN1; SMN2ATR | |
| SCHEMBL7980768 | 0.85 | KDR (0.45) | KDRFLT1FLT4MAPTTP53 | |
| SCHEMBL7739018 | 0.84 | KDR (0.62) | HPNKDRFLT1FLT4SMN1; SMN2 | |
| SCHEMBL7739072 | 0.83 | KDR (0.43) | HPNKDRFLT1FLT4SMN1; SMN2 | |
| SCHEMBL7744175 | 0.81 | KDR (0.49) | HPNKDRFLT1FLT4SMN1; SMN2 | |
| SCHEMBL7744063 | 0.81 | KDR (0.54) | HPNKDRFLT1FLT4SMN1; SMN2 | |
| SCHEMBL7744641 | 0.81 | KDR (0.55) | HPNKDRFLT1FLT4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097147-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | claimed |
| EP-1097147-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2001-05-09 | — | — | EP | claimed |
| US-6228871-B1 | THIAZOLE OR OXAZOLE DERIVATIVE TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; AUTOIMMUNE DISEASES; DIABETIC RETINOPATHY | MERCK & CO., INC. | 2001-05-08 | — | — | US | claimed |
| WO-2000002871-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 2000-01-20 | — | — | WO | claimed |
| EP-1097147-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1097147-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6228871-B1 | THIAZOLE OR OXAZOLE DERIVATIVE TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; AUTOIMMUNE DISEASES; DIABETIC RETINOPATHY | MERCK & CO., INC. | 2001-05-08 | — | — | US | disclosed |
| WO-2000002871-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 2000-01-20 | — | — | WO | disclosed |